{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:49:28Z","timestamp":1792532968675,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.clinthera.2026.06.020","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:28:18Z","timestamp":1785410898000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitors in NSCLC: Insights From Pharmacovigilance Data, a Retrospective Case-control Study, and Single-cell RNA Sequencing Dataset"],"prefix":"10.1016","author":[{"given":"Xiaoyu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijia","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongjun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingxiu","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clinthera.2026.06.020_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"10.1016\/j.clinthera.2026.06.020_bib0002","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","article-title":"The global burden of lung cancer: current status and future trends","volume":"20","author":"Leiter","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"10.1016\/j.clinthera.2026.06.020_bib0003","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1200\/JCO.20.01605","article-title":"Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer","volume":"39","author":"Borghaei","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clinthera.2026.06.020_bib0004","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 Study","volume":"41","author":"Garassino","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clinthera.2026.06.020_bib0005","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41571-025-01035-9","article-title":"The next generation of immunotherapies for lung cancers","volume":"22","author":"Zhao","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"10.1016\/j.clinthera.2026.06.020_bib0006","doi-asserted-by":"crossref","first-page":"e1056","DOI":"10.1210\/clinem\/dgad231","article-title":"Risk of thyroid dysfunction in PD-1 blockade is stratified by the pattern of TgAb and TPOAb positivity at baseline","volume":"108","author":"Zhou","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.clinthera.2026.06.020_bib0007","doi-asserted-by":"crossref","first-page":"e1620","DOI":"10.1210\/clinem\/dgab829","article-title":"Increased risk of thyroid dysfunction by PD-1 and CTLA-4 blockade in patients without thyroid autoantibodies at baseline","volume":"107","author":"Iwama","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.clinthera.2026.06.020_bib0008","doi-asserted-by":"crossref","first-page":"e4115","DOI":"10.1210\/clinem\/dgac467","article-title":"Elevated TSH level, TgAb, and prior use of ramucirumab or TKIs as risk factors for thyroid dysfunction in PD-L1 blockade","volume":"107","author":"Kobayashi","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.clinthera.2026.06.020_bib0009","doi-asserted-by":"crossref","first-page":"e3704","DOI":"10.1210\/clinem\/dgab263","article-title":"Thyroid immune-related adverse events following immune checkpoint inhibitor treatment","volume":"106","author":"Muir","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.clinthera.2026.06.020_bib0010","doi-asserted-by":"crossref","first-page":"144","DOI":"10.17305\/bb.2025.12321","article-title":"Impact of thyroid immune-related adverse events on clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with checkpoint inhibitor therapy: a single center study","volume":"26","author":"Ceri\u0107","year":"2025","journal-title":"Biomol Biomed"},{"issue":"9","key":"10.1016\/j.clinthera.2026.06.020_bib0011","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16091764","article-title":"Endocrine immune-related adverse events are independent predictors of survival in patients with lung cancer","volume":"16","author":"Panagiotou","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clinthera.2026.06.020_bib0012","article-title":"Immune checkpoint inhibitors-induced thyroid dysfunction improves the prognosis of patients with lung cancer: a meta-analysis and systematic review","volume":"16","author":"Dong","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"10.1016\/j.clinthera.2026.06.020_bib0013","doi-asserted-by":"crossref","DOI":"10.1530\/EC-25-0305","article-title":"Disproportionality analysis and risk factor assessment of drug-associated thyroid dysfunction adverse events: a study based on the FAERS database","volume":"14","author":"Wang","year":"2025","journal-title":"Endocr Connect"},{"issue":"10","key":"10.1016\/j.clinthera.2026.06.020_bib0014","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011865","article-title":"Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors","volume":"13","author":"Zhu","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.clinthera.2026.06.020_bib0015","article-title":"A standardized dataset of a spontaneous adverse event reporting system","volume":"10","author":"Khaleel","year":"2022","journal-title":"Healthcare (Basel)"},{"key":"10.1016\/j.clinthera.2026.06.020_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1453429","article-title":"Delayed immune-related adverse events profile associated with immune checkpoint inhibitors: a real-world analysis","volume":"15","author":"Yang","year":"2024","journal-title":"Front Pharmacol"},{"issue":"8","key":"10.1016\/j.clinthera.2026.06.020_bib0017","doi-asserted-by":"crossref","first-page":"5105","DOI":"10.1097\/JS9.0000000000002607","article-title":"Immunotherapy-induced cholestasis in cancer: insights from the two real-world pharmacovigilance databases of FAERS and VigiBase","volume":"111","author":"Yan","year":"2025","journal-title":"Int J Surg."},{"issue":"6","key":"10.1016\/j.clinthera.2026.06.020_bib0018","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/pds.2247","article-title":"Are all quantitative postmarketing signal detection methods equal? Performance characteristics of logistic regression and multi-item gamma poisson shrinker","volume":"21","author":"Berlin","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"10.1016\/j.clinthera.2026.06.020_bib0019","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1007\/s00262-022-03151-2","article-title":"Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors","volume":"71","author":"von Itzstein","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clinthera.2026.06.020_bib0020","article-title":"Clinical manifestations and risk factors of immune-related thyroid adverse events in patients treated with PD-1 inhibitors: a case-control study","volume":"16","author":"Zhao","year":"2025","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.clinthera.2026.06.020_bib0021","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-71746-z","article-title":"Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the MOUSEION-07 systematic review and meta-analysis","volume":"14","author":"Vitale","year":"2024","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.clinthera.2026.06.020_bib0022","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/intimm\/dxl151","article-title":"Treg suppressive activity involves estrogen-dependent expression of programmed death-1 (PD-1)","volume":"19","author":"Polanczyk","year":"2007","journal-title":"Int Immunol."},{"issue":"2","key":"10.1016\/j.clinthera.2026.06.020_bib0023","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1093\/oncolo\/oyab043","article-title":"Immune checkpoint inhibitor-related new-onset thyroid dysfunction: a retrospective analysis using the US FDA adverse event reporting system","volume":"27","author":"Lu","year":"2022","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.clinthera.2026.06.020_bib0024","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1210\/clinem\/dgad670","article-title":"Risk and incidence of endocrine immune-related adverse effects under checkpoint inhibitor mono- or combination therapy in solid tumors: a meta-analysis of randomized controlled trials","volume":"109","author":"Vardarli","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.clinthera.2026.06.020_bib0025","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline","volume":"187","author":"Husebye","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.clinthera.2026.06.020_bib0026","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.pathol.2019.10.010","article-title":"Unique and distinctive histological features of immunotherapy-related thyroiditis","volume":"52","author":"Zaborowski","year":"2020","journal-title":"Pathology"},{"key":"10.1016\/j.clinthera.2026.06.020_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.606056","article-title":"Pembrolizumab-induced thyroiditis shows PD-L1expressing histiocytes and infiltrating T cells in thyroid tissue: a case report","volume":"12","author":"Jabkowski","year":"2021","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.clinthera.2026.06.020_bib0028","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1089\/thy.2021.0165","article-title":"Distinct cytokine signatures in thyroiditis induced by PD-1 or CTLA-4 blockade: insights from a new mouse model","volume":"31","author":"Ippolito","year":"2021","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.clinthera.2026.06.020_bib0029","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13256-018-1708-x","article-title":"Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with Hashimoto's disease and diabetes mellitus: a case report","volume":"12","author":"Yonezaki","year":"2018","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.clinthera.2026.06.020_bib0030","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-214603","article-title":"A rare case of thyroid storm","volume":"2016","author":"McMillen","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.clinthera.2026.06.020_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1392956","article-title":"Immune checkpoints: new insights into the pathogenesis of thyroid eye disease","volume":"15","author":"Shu","year":"2024","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.clinthera.2026.06.020_bib0032","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1507\/endocrj.EJ23-0524","article-title":"Clinical characteristics and potential biomarkers of thyroid and pituitary immune-related adverse events","volume":"71","author":"Kobayashi","year":"2024","journal-title":"Endocr J"},{"issue":"5","key":"10.1016\/j.clinthera.2026.06.020_bib0033","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41574-024-01077-6","article-title":"Management, biomarkers and prognosis in people developing endocrinopathies associated with immune checkpoint inhibitors","volume":"21","author":"Iwama","year":"2025","journal-title":"Nat Rev Endocrinol"},{"issue":"15","key":"10.1016\/j.clinthera.2026.06.020_bib0034","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1001\/jama.2026.1114","article-title":"Obesity and Cancer: a translational science review","volume":"335","author":"Shen","year":"2026","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.clinthera.2026.06.020_bib0035","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nri2921","article-title":"Adipokines in inflammation and metabolic disease","volume":"11","author":"Ouchi","year":"2011","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"10.1016\/j.clinthera.2026.06.020_bib0036","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa458","article-title":"Immune checkpoint inhibitor-induced thyroid dysfunction is associated with higher body mass index","volume":"105","author":"Pollack","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.clinthera.2026.06.020_bib0037","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.eprac.2024.03.023","article-title":"Endocrinopathies associated with immune checkpoint inhibitor use","volume":"30","author":"Kotwal","year":"2024","journal-title":"Endocr Pract"},{"issue":"36","key":"10.1016\/j.clinthera.2026.06.020_bib0038","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clinthera.2026.06.020_bib0039","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.clinthera.2026.06.020_bib0040","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nri2803","article-title":"Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules","volume":"10","author":"de Saint Basile","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.clinthera.2026.06.020_bib0041","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.immuni.2018.01.007","article-title":"Human T cell development, localization, and function throughout life","volume":"48","author":"Kumar","year":"2018","journal-title":"Immunity"},{"issue":"696","key":"10.1016\/j.clinthera.2026.06.020_bib0042","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg0675","article-title":"Clonally expanded, thyrotoxic effector CD8(+) T cells driven by IL-21 contribute to checkpoint inhibitor thyroiditis","volume":"15","author":"Lechner","year":"2023","journal-title":"Sci Transl Med"},{"issue":"9","key":"10.1016\/j.clinthera.2026.06.020_bib0043","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2022111494","article-title":"Antitumor T-cell function requires CPEB4-mediated adaptation to chronic endoplasmic reticulum stress","volume":"42","author":"Fern\u00e1ndez-Alfara","year":"2023","journal-title":"EMBO J"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826002353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826002353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T19:21:23Z","timestamp":1786303283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291826002353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":43,"alternative-id":["S0149291826002353"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.06.020","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitors in NSCLC: Insights From Pharmacovigilance Data, a Retrospective Case-control Study, and Single-cell RNA Sequencing Dataset","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}